ArticleTraffic (Copenhagen, Denmark)2009
Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery.
Article in Traffic (Copenhagen, Denmark), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 75 citations in OpenAlex.
- Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses.Science advances · 2019Trial
- Integrative structural insights into the IgG-FcRn interactions revealed by engineered FcRn-immobilized affinity chromatography.Communications biology · 2026Article
- Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Engineering FcRn binding kinetics dramatically extends antibody serum half-life and enhances therapeutic potential.Journal of biological engineering · 2025Article
- FcRn-guided antigen trafficking enhances cancer vaccine efficacy.Cancer immunology, immunotherapy : CII · 2025Article
- Engineering of pH-dependent antigen binding properties for toxin-targeting IgG1 antibodies using light-chain shuffling.Structure (London, England : 1993) · 2024Article
- Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review.International journal of molecular sciences · 2022Review
- Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life.iScience · 2022Article
- Strategies Towards Antigen-Specific Treatments for Membranous Nephropathy.Frontiers in immunology · 2022Review
- Research progress on neonatal Fc receptor and its application.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2021Review
- Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway.Cell chemical biology · 2021Review
- Analysis of the intracellular traffic of IgG in the context of Down syndrome (trisomy 21).Scientific reports · 2021Article
- Article
- Fate of the Fc fusion protein aflibercept in retinal endothelial cells: competition of recycling and degradation.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019Article
- A two-stage method for automated detection of ring-like endosomes in fluorescent microscopy images.PloS one · 2019Article
- Targeting FcRn to Generate Antibody-Based Therapeutics.Trends in pharmacological sciences · 2018Review
- Review
- Phagocytosis of antibody-opsonized tumor cells leads to the formation of a discrete vacuolar compartment in macrophages.Traffic (Copenhagen, Denmark) · 2018Article
- A human endothelial cell-based recycling assay for screening of FcRn targeted molecules.Nature communications · 2018Article
- Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin.The Journal of biological chemistry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Lysosomes play a central role in the degradation of proteins and other macromolecules. The mechanisms by which receptors are transferred to lysosomes for constitutive degradation are poorly understood. We have analyzed the processes that lead to the lysosomal delivery of the Fc receptor, FcRn. These studies provide support for a novel pathway for receptor delivery. Specifically, unlike other receptors that enter intraluminal vesicles in late endosomes, FcRn is transferred from the limiting membrane of such endosomes to lysosomes, and is rapidly internalized into the lysosomal lumen. By contrast, LAMP-1 persists on the limiting membrane. Receptor transfer is mediated by tubular extensions from late endosomes to lysosomes, or by interactions of the two participating organelles in kiss-and-linger-like processes, whereas full fusion is rarely observed. The persistence of FcRn on the late endosomal limiting membrane, together with selective transfer to lysosomes, allows this receptor to undergo recycling or degradation. Consequently, late endosomes have functional plasticity, consistent with the presence of the Rab5 GTPase in discrete domains on these compartments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.